In vitro activities of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae

Insights of synthetic analogues of anti-leprosy agents

Today, the emergence of the phenomenon of drug or multidrug-resistance for community-associated diseases represents a major concern in the world. In these contexts, the chronic infectious disease, leprosy, grounded by a slow-growing bacterium called Mycobacterium leprae or Mycobacterium lepromatosis is a leadingcause of severe disfiguring skin sores and nerve damage in the arms, legs, and skin areas around the body. Even, over 200,000 new leprosy cases are being accounted every year along with the relapsed leprosy cases. Nonetheless, this has been considered a curable disease with a higher dose of multidrug therapy (MDT) for a long period of time. The prolonged action of a high dose of combination drugs administration may cause an adverse reaction that can significantly affect patient compliance, particularly the outbreak of multidrug-resistance in the infected person. To overcome these shortfalls or prevent the resistance-associated problems, researchers are diligently involved in the structural modifications of the clinically used anti-leprosy drugs or the allied compounds for the structure-antimycobacterial activity relationship study. This review article described the detailed synthesis and biological assays of different anti-leprosy compounds reported by several research groups.

Rifampicin: an inhibitor of Xp12-specific protein phosphorylation in Xanthomonas oryzae pv. oryzae

Phosphorylation of the three Xp12-specific phosphoproteins was drastically reduced by rifampicin, an antibiotic that specifically inhibits the host-cell RNA polymerase. However, this inhibitory effect could not be found in spontaneous mutants of Xanthomonas oryzae pv. oryzae whose RNA polymerase are resistant to the drug. The inhibitory effect of rifampicin treatment also resulted suppression of the Xp12 multiplication cycle. This implies the physiological significance of this effect and supports our previous prediction that phosphorylation plays an important role in the life cycle of Xp12. The acid- and alkali-labile character of the Xp12-specific phosphoproteins and the chemical stability of the phosphoryl linkages show that the corresponding protein kinase catalyzes the formation of an acyl phosphorylation. Subsequent fractionation of cell lysate revealed that the phosphoproteins were located in the periplasm. Actinomycin D, which affects transcription through DNA condensation rather than its binding to RNA polymerase, was not able to cause the inhibition effect. On the other hand, cerulenin was found to reduce the acyl phosphorylation which hints at a possible role of cell membrane in the phosphorylation. Here we present the evidence for the functional involvement of the rifampicin treatment on protein phosphorylation. A possible mechanism of rifampicin on the alternation of acyl phosphorylation is proposed.

Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy

Rifabutin is a derivative of rifamycin S with activity against mycobacteria including atypical organisms such as Mycobacterium avium and M. intracellulare, also referred to as Mycobacterium avium-intracellulare complex (MAC). To date, rifabutin is the only drug to have been studied in large prospective placebo-controlled trials that has been shown to significantly reduce the incidence of disseminated MAC infection when administered prophylactically as a single agent to patients with acquired immune deficiency syndrome (AIDS). Initial studies also indicate that rifabutin may be a useful component of multiple drug regimens for the treatment of MAC infection, although further studies combining rifabutin with other recently available antimycobacterial drugs are required to determine the most effective regimens. When rifabutin is combined with at least two other antimycobacterial drugs, the combination appears to be of similar efficacy to rifampicin (rifampin)-containing regimens in patients with newly diagnosed pulmonary tuberculosis. Since available therapy for MAC infection in patients with AIDS is still suboptimal, rifabutin, at present the only first-line agent for prophylaxis against disseminated MAC infection in patients with advanced human immunodeficiency virus (HIV) infection, has the potential to make a valuable contribution to the continuing attempts to preserve the quality of life of patients with AIDS.

Fusidic acid is highly active against extracellular and intracellular Mycobacterium leprae

The activity of fusidic acid against Mycobacterium leprae was studied in axenic medium and in bacilli residing within mouse peritoneal macrophages. Activity was assessed by subsequent quantitation of bacillary radiorespirometric activity. Significant inhibition in both systems was observed at 0.156 micrograms/ml, and an approximately 50% reduction in activity occurred after exposure to 1.25 to 2.5 micrograms/ml. The excellent human pharmacokinetics and in vitro activity of fusidic acid against the leprosy bacillus warrant a clinical trial of this drug for leprosy.